Key facts
- It has raised $48.8M; the latest was Later Stage VC ($9.2M) in Oct 2025.
- Notable investors include KB Investment, IMM Investment, Mirae Asset Capital, STIC Ventures, Partners Investment — 26 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 26 names
- ·Watchlist + deal alerts for PinotBio
- ·The full record, as it builds
Funding rounds
No funding rounds for PinotBio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About PinotBio
Bionet Therapeutics Corp is a patient-focused on regenerative medicinal products, R&D, exosomes, and gene/cell therapy biopharmaceutical company. The group develops, manufactures, and provides regenerative medicine preparations and cellular therapies to meet the evolving health needs of people at different stages of life. It focused on treatments that improve patient outcomes. It provides Cell Therapy Products and CRDMO Services.
- Sector
- Healthcare
- HQ
- Suwon, South Korea
- Founded
- 2017
- Employees
- 105
- Website
- pinotbio.com/
- Ownership
- Privately Held (backing)
PinotBio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in PinotBio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on PinotBio in its N-PORT filings yet. We sweep new filings monthly.